Home  »  Ipo Review  »  Windlas Biotech Ipo

Let’s have a detailed review of the company and analytics of the Windlas Biotech IPO release date, IPO offer price, subscription, Windlas Biotech Limited IPO allotment, grey market price, and other details like the company’s background, its financial positions, its promoters, and other related things.

Face Value Rs 5
Cash Price Rs 448 to Rs 460
Listing At BSE, NSE
Min. Order Quantity 30 Shares
Listing Date Aug 17, 2021
Offer for Sale Rs 2365.40 Million
Fresh Issue Rs 1,650 Million
IPO Size Rs 4015.40 Million
Tick Size 1

Windlas Biotech IPO is listed at a [●] premium. Check out the live share price by clicking on the below link.

Windlas Biotech IPO – Summary

Windlas Biotech IPOThey are amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue (Source: CRISIL Report).

With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances, and low solubility, They provide a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (“GMP”) with a focus on improved safety, efficacy and cost.

The Promoter of this company is Mr. Ashok Kumar Windlass. The lead manager to the issue is SBI Capital Markets Limited, DAM Capital Advisors Limited, and IIFL Securities Limited, The Registrar to this issue is Link Intime India Private Limited.

Windlas Biotech IPO Date

The opening and the closing date of the IPO of Windlas Biotech Limited are Aug 4, 2021, and Aug 6, 2021, respectively.

Windlas Biotech IPO Subscription

Day / Date QIB NII RII Total Subscription
1st Day – 04 August 0.00x 0.34x 6.15x 3.17x
2nd Day –  05 August 0.04x 1.12x 13.52x 7.06x
3rd Day – 06 August 24.40x 15.73x 24.22x 22.44x
Shares Offered or Net Issue 1,723,700 1,323,766 3,088,786 6,136,252

The shares subscribed by the public will be updated here.

Check Windlas Biotech IPO LIVE Subscription

  • Windlas Biotech IPO LIVE Bid details on BSE
  • Windlas Biotech IPO LIVE Bid details on NSE

For the Latest Bid details click on the above links.

Windlas Biotech IPO Allotment Status

Here, you can find the Allotment Status of this IPO.

Allotment of Equity Shares pursuant to the Fresh Issue and transfer of the Offered Shares of the Promoter Selling Shareholders pursuant to the Offer for Sale to the successful Bidders. However, the Allotment Status is not yet disclosed.

Windlas Biotech Limited IPO Listing Date

Find the dates below on basis of allotment, refund, listing, and more:

Basis of Allotment Finalization Aug 11, 2021
Refunds Initiation Aug 12, 2021
The credit of Shares to Demat Account Aug 13, 2021
Share Listing Date Aug 17, 2021

Windlas Biotech IPO Cash Price

The face value of each share is Rs.5, but the Cash price of the IPO is Rs 448 to Rs 460 

Windlas Biotech IPO Equity Size

This Initial Public Issue of X Equity Shares of Rs.5 each for cash at a price of Rs 448 to Rs 460 per equity share aggregating to Rs.4015.40 million

Windlas Biotech IPO Share Offering

Fresh Issue: The Issue (excluding the Market Maker Reservation Portion) of [●] Equity Shares of Rs.10/ each.

Issue Size: X Equity Shares of Rs.5 each, aggregating to Rs.4015.40 Million

Open Free Demat Account Now!

    Fill Your Details Here
    1. Open Demat AccountInvest in IPO

    Windlas Biotech IPO – Live Performance

    The listing date of this IPO is Aug 17, 2021. You can check the live performance of the IPO here, only after it is listed on exchanges.

    Live IPO Performance – Windlas Biotech Share Price

    Windlas Biotech IPO Grey Market Premium

    The Windlas Biotech Limited IPO Grey Market Premium price is Rs 85, the Kostak rate is Rs 0 and the Subject to Sauda is Rs 0. 

    Windlas Biotech IPO – Company Overview

    The prevalence of chronic diseases in India has been increasing in the last few years, specifically in certain key therapeutic categories, such as, anti-diabetic, cardiovascular, neuropsychiatry, and respiratory therapies, that are treated with ‘multi-drug therapy’ by physicians, i.e. the specific use of two or more drugs for single or multiple chronic conditions in an individual.

    Moreover, multi-drug therapy has gained importance over the past few years in the healthcare sector and is expected to aid the growth of pharmaceutical consumption. (Source: CRISIL Report). They have significant experience in developing and manufacturing generic fixed-dose combinations.

    Our focus has currently been on launching new complex generic products in the chronic therapeutic category linked to lifestyle-related disorders.

    Windlas Biotech IPO – Financial Statements

    A quick look into the past financial performance of the company to understand its performance of the business and evaluate the growth prospectus:

    Financial Summary:

    Amount (in INR & Million)
    31-Mar-21 31-Mar-20 Mar-19
    Total Assets 2,961.23 3,384.88 2,981.80
    *Total Revenue 4,306.95 3,313.39 3,115.25
    Total Expense 3,871.65 2,992.05 2,841.88
    Profit After Tax 155.70 162.13 638.22

    Earnings per Equity Share (in Million)

    31-Mar-21 31-Mar-20 Mar-19
    Basic 8.70 8.90 38.61
    Diluted 8.70 8.90 37.65


    Further, their PAT for the period ended on March 31, 2021, March 31, 2020, and March 31, 2019, were Rs. 155.70 Million, Rs. 162.13 Million, and Rs. 638.22 Million respectively.

    Windlas Biotech IPO – Promoters

    The Promoter of this company is:

    1. Ashok Kumar Windlass

    List of Related Parties (Key Managerial Personnel)

    • Mr. Vivek Dhariwal, Chairman and Non-Executive Independent Director
    • Mr. Ashok Kumar Windlass, Wholetime Director
    • Mr. Hitesh Windlass, Managing Director
    • Mr. Manoj Kumar Windlass, Joint Managing Director.
    • Mr. Pawan Kumar Sharma, Executive Director.

    Windlas Biotech IPO – Promoters Holding

    • Pre Issue Share Holding – 78%
    • Post Issue Share Holding – 65.16 %

    Windlas Biotech IPO Offer Details or Issue Details

     Particulars  No. Of Equity Shares
     Equity Shares Offered  Up to X Equity Shares aggregating up to Rs.4015.40 Million
    of which:
    Fresh Issue Up to [●] Equity Shares aggregating up to Rs.1,650 million.
    Net Issue to the Public Up to 5,142,067 Equity Shares aggregating up to Rs.2365.40 Million
    Of which:
    Retail Investors Portion Not less than [●] Equity Shares
    Other than Retail Individual Investors Not more than [●] Equity Shares
     Equity Shares outstanding prior to the Issue 18,207,419 Equity Shares
     Equity Shares outstanding after the Issue X Equity Shares

    Windlas Biotech IPO Issue Object

    Their Company proposes to utilize the Net Proceeds towards funding the following objects:

    1. Purchase of equipment required for (i) capacity expansion of our existing facility at Dehradun Plant – IV; and (ii) addition of injectables dosage capability at our existing facility at Dehradun Plant-II;
    2. General Corporate Purpose
    3. To meet issue expenses
    4. Repayment/prepayment of certain of our borrowings

    Windlas Biotech IPO – Business Strategy

    • Capitalize on expansion opportunities by leveraging our leadership position in the CDMO industry
    • Continue to grow our CDMO customer base
    • Expand our product portfolio and delivery systems by enhancing R&D and manufacturing capabilities
    • Focus on the Domestic Trade Generics and OTC Brands SBV and high growth export markets by capitalizing on industry

    Windlas Biotech IPO – Basis of Offer Price

    The issue price is determined by the company in consultation with the Lead manager on the basis of the following qualitative and quantitative factors.

    Qualitative factors are:

    • Leading CDMO in India with a focus on the chronic therapeutic category
    • Innovative portfolio of complex generic products supported by robust R&D capabilities
    • Efficient and quality compliant manufacturing facilities with significant entry barriers
    • Strong and long-term relationships with leading Indian pharmaceuticals companies

    The relevant quantitative factors are:

    Basic EPS   Diluted EPS RONW (%) NAV (Rs.)
    31-Mar-21 8.70 8.70 18.19 109.36
    31-Mar-20 8.90 8.90 8.04
    Mar-19 38.61 37.65 8.97

    Windlas Biotech IPO: Competitive Peers

    Face Value (Rs.) P/E EPS  (Rs.) Return on Net Worth (%) Total Income (Rs. in Million)
    Windlas Biotech Limited 5 [●]
    Listed Peers
    NA 10 NA NA

    Windlas Biotech IPO Lead Managers

    Lead Managers

    SBI Capital Markets Limited,

    DAM Capital Advisors Limited,

    IIFL Securities Limited

    Windlas Biotech IPO Registrar to offer

    Registrar to the Offer
    Link Intime India Private Limited
    C-101, 1st Floor 247 Park, Lal Bhadur Shastri Marg
    Vikhroli (West), Mumbai 400 083, Maharashtra, India
    Tel: +91 22 4918 6200
    E-mail: windlas.ipo@linkintime.co.in
    Website: www.linkintime.co.in
    Investor Grievance ID:
    Contact Person: Shanti Gopalkrishnan
    SEBI Registration Number: INR000004058

    Windlas Biotech IPO – Other Details

    • Statutory Auditor – S. S. Kothari Mehta & Company
    • Legal Counsel to the Company – Cyril Amarchand Mangaldas
    • Bankers to the Company – State Bank of India, HDFC Bank Ltd. IndusInd Bank Limited.

    Windlas Biotech IPO Review by Stock Brokers

    Top Stock Brokers Review Company Reputation Competitive Edge Financial Statement Popularity Index Promoters Reputation
    Angel Broking 7.5/10 7.4/10 8.5/10 8.1/10 7.1/10
    Sharekhan 7.2/10 7.1/10 8.6/10 8.1/10 7.2/10
    Kotak Securities 7.3/10 7.5/10 8.4/10 8.1/10 7.3/10
    ICICI Direct 7.3/10 7.3/10 8.7/10 8.1/10 7.1/10
    IIFL 7.5/10 7.2/10 8.8/10 8.0/10 7.1/10
    Edelweiss 7.5/10 7.4/10 8.4/10 8.3/10 7.2/10
    Zerodha 7.4/10 7.1/10 8.5/10 8.1/10 7.0/10
    5Paisa 7.1/10 7.1/10 8.4/10 8.1/10 7.1/10
    Karvy 7.4/10 7.3/10 8.2/10 8.1/10 7.1/10
    Motilal Oswal 7.1/10 7.1/10 8.6/10 8.3/10 7.2/10


    Subscribe to Windlas Biotech IPO

      Fill Your Details Here
      1. Open Demat AccountInvest in IPO

      Windlas Biotech Limited IPO News

      News 1 – IPO DRHP Download

      News 2 – IPO RHP Prospectus Download

      Windlas Biotech IPO Review FAQs

      Ques – What is the Issue Size of Windlas Biotech IPO?

      Answer – The Company is making an initial public offer of NA equity shares. We vividly portray the aspects of the issue in this article. You can check the stats on the fresh issue, Offer for sale, and net issue.

      Ques – What is the Cash Price of Windlas Biotech IPO?

      Answer – The Cash price for this particular IPO Is Rs 448 to Rs 460. As far as the face value of the share is of concern, it is Rs.5 per share.

      Ques – What is the Windlas Biotech IPO Open Date?

      Answer – The opening and closing dates for this IPO have been updated. The IPO is set to open on Aug 4, 2021, while the closing date is set at Aug 6, 2021.

      Ques – What is the Windlas IPO Allotment Date?

      Answer – We also have the news regarding the respective allotment dates of this IPO. The basis of Allotment finalization is on Aug 11, 2021, refund initiation is on Aug 12, 2021, credit of shares is on Aug 13, 2021, and share listing date is on Aug 17, 2021.

      Ques – What is the Windlas Biotech IPO Listing Date?

      Answer – Shares of this company shall be listed in the exchanges on Aug 17, 2021. The date, when the listing would be done, is stagnant on Aug 17, 2021.

      Ques – Who is the Registrar of Windlas IPO?

      Answer – One of the reputed registrars is managing the issue of this IPO, i.e. Link Intime India Private Limited. Their website will help you regarding the further information you are on the lookout for.

      Ques – Who is the Promoter of Windlas IPO?

      Answer – Here are the promoters of this IPO -Ashok Kumar Windlass You can refer to the RHP for further information on the promoter. You will find the link to RHP in the article.

      Ques – What is the GMP of Windlas Biotech IPO?

      Answer – We have obtained the GMP of this IPO and it is Rs 85. Further insights of Kostak rate and subject to sauda or SS are as well included in this report.

      Ques – Is Windlas IPO good for Investment?

      Answer – We have further provided the financial status of the company in this article, from the past few years. You can refer to the same, and also check the line of operations they are into and then decide to invest in the IPO.

      Ques – What is the PAT of Windlas Biotech Ltd?

      Answer – We have the information of company financials, and according to that, we have the figures from the last few years to provide. Their PAT for the period ended on March 31, 2021, March 31, 2020, and March 31, 2019, were Rs. 155.70 Million, Rs. 162.13 Million, and Rs. 638.22 Million respectively.

      Calculate your return on investment!

      Asset Class ROI (Rs.) Profit (Rs.) Profit (%)
      Real Estate
      Fixed Deposit
      Mutual Fund

      Featured Topics


      Get 100% IPO Allotment Guarantee! Subscribe to IPO